In the initial PALOMA-2 (NCT01740427) analysis, the median follow-up was 23 months, and palbociclib calais can significantly prolong estrogen receptor-positive (ER-plus)/human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC) women's progression-free survival (PFS) (PFS) (risk ratio (HR) 0.58; Here, we report on the overall and sub-group results of extended follow-up visits
In this two-blind, phase 3 study, postmenopausal women with ER/HER2-ABC were randomly assigned to palbolibcic-letrozole or placebo-letrozole in a 2:1 ratio if they had not received previous systematic treatment for their advanced illnessThe endpoint includes PFS (primary), safety, and patient-reported results (PRO) assessed by the researchers
The results showed that after approximately 38 months of median follow-up, the median PFS for palbociclib-letrozole (n s 444) was 27.6 months, and the median PFS for placebo-letrozole (n s 222) was 14.5 months (HR 0.563; unilateral P .0001)All subgroups benefit edified from palbociclib treatmentIn the next 2-line treatment, the improvement in PFS was maintained and the use of chemotherapy was delayed (palbociclib-letrozole vsplacebo-letrozole 40.4 vs29.9 months)Security data is consistent with known informationThe quality of life of patients is maintained
Overall, the results showed that, after approximately 15 months of additional follow-up, palbocicoctazole continued to show improvement in PFS in the overall population and in all patient subgroups compared to placebo-lacazola, while safety data remained good and quality of life was maintainedThese data confirm that palbociclib-letrozole should be considered as standard treatment for first-line treatment in patients with ER/HER2-ABC, including patients with low or disease-free intervals
